For too long, healthcare providers have had few options to offer ... Johnson & Johnson Innovative Medicine. "SPRAVATO ® is now available as a standalone treatment, meaning patients may experience ...

Spravato is a form of esketamine that patients take as a self-administered nasal spray under the supervision of a healthcare provider. Esketamine and ketamine are mirror molecules that together form ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

For too long, healthcare providers have had few options to offer patients' much-needed symptom improvement," said Bill Martin, J&J's global therapeutic area head for neuroscience. "Spravato is now ...

Spravato is taken by the user under the supervision of a healthcare provider in a clinic. Because reported side-effects include temporary nausea, vomiting, and tiredness, healthcare supervisors ...

"Spravato is intended to be administered under direct supervision by a healthcare provider," says Yvette Sheline, MD, director of the Center for Neuromodulation in Depression and Stress at the ...

“Now that it is also available as a monotherapy, healthcare providers have the freedom ... Charles Psychiatric Associates, said in a statement. Spravato bought in sales of $780 million for ...

Spravato is classified as a Schedule III controlled ... it must be administered under the direct supervision of a health care provider. A treatment session consists of nasal administration and ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA ...